Safety Study of Recombinant M2e Influenza-A Vaccine in Healthy Adults
Completed
This multi-center study will be conducted in the United States with up to 80 healthy adult subjects. Subjects will be scheduled to receive a total of two (2) injections with 1 injection each administered. Subjects will be randomized according to a randomization scheme.
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
01/16/2012
Locations: Miami Research Associates, Miami, Florida
Conditions: Influenza
Double Blind, Safety and Immunogenicity Study of Recombinant Botulinum Vaccine A/B
Completed
This Phase 2 study is a double blind, placebo-controlled, randomized, multicenter investigation of rBV A/B-40 vaccine or placebo in healthy adults, using two different three-dose dosing schedules.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
11/28/2011
Locations: Miami Research Associates, Miami, Florida +1 locations
Conditions: Botulism Vaccine
MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma
Completed
The purpose of this study is to determine the safety and efficacy of MDX-010 (ipilimumab, BMS-734016) (anti-CTLA4) in combination with MDX-1379 (gp100, BMS-734019) in patients with previously treated, unresectable Stage III or IV melanoma. Survival time will be evaluated, as well as patient responses and time to disease progression. Eligible patients are those who in response to a single regimen containing interleukin-2 (IL-2), dacarbazine, and/or temozolomide, have 1) relapsed following an obje... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2011
Locations: Mount Sinai Comprehensive Cancer Center at Aventura, Aventura, Florida +12 locations
Conditions: Melanoma, Metastases
Safety and Efficacy Study of Fluzone® Vaccine Combined With Different Doses of JVRS-100 Adjuvant
Completed
This study is designed to assess safety, tolerability and immunogenicity of Fluzone® vaccine with four dose levels of JVRS-100 adjuvant compared to Fluzone® vaccine alone in healthy adults 18-49 years of age.
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
03/15/2010
Locations: Miami Research Associates, Miami, Florida
Conditions: Influenza